Moderna (MRNA) Projected to Post Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Friday, August 1st. Analysts expect Moderna to post earnings of ($2.97) per share and revenue of $116.26 million for the quarter. Moderna has set its FY 2025 guidance at EPS.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company's quarterly revenue was down 35.3% on a year-over-year basis. During the same period in the prior year, the business earned ($3.07) earnings per share. On average, analysts expect Moderna to post $-10 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Moderna Trading Up 0.4%

Shares of MRNA stock traded up $0.14 during trading hours on Friday, hitting $34.15. The company's stock had a trading volume of 5,367,762 shares, compared to its average volume of 9,132,097. Moderna has a twelve month low of $23.15 and a twelve month high of $125.68. The business has a fifty day moving average of $28.58 and a 200-day moving average of $30.68. The stock has a market cap of $13.21 billion, a price-to-earnings ratio of -3.91 and a beta of 1.84.

Institutional Investors Weigh In On Moderna

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. United Services Automobile Association acquired a new position in Moderna during the 1st quarter worth $230,000. NewEdge Advisors LLC grew its position in shares of Moderna by 732.7% during the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company's stock valued at $328,000 after buying an additional 10,185 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Moderna during the 1st quarter valued at about $415,000. Finally, Focus Partners Wealth grew its position in shares of Moderna by 58.7% during the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company's stock valued at $668,000 after buying an additional 8,706 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Barclays restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. William Blair restated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Royal Bank Of Canada decreased their target price on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Finally, Bank of America decreased their price target on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a report on Tuesday. Four research analysts have rated the stock with a sell rating, seventeen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $46.11.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.